CN107137628A - Hyaluronidase inhibitor and its application from symbiotic fermentation product - Google Patents
Hyaluronidase inhibitor and its application from symbiotic fermentation product Download PDFInfo
- Publication number
- CN107137628A CN107137628A CN201610108181.9A CN201610108181A CN107137628A CN 107137628 A CN107137628 A CN 107137628A CN 201610108181 A CN201610108181 A CN 201610108181A CN 107137628 A CN107137628 A CN 107137628A
- Authority
- CN
- China
- Prior art keywords
- bcrc
- atcc
- lactobacillus
- hyaluronidase
- fermentation product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of Hyaluronidase inhibitor, it includes symbiotic fermentation product, and this symbiotic fermentation product is to be obtained in vegetalitas culture medium using a variety of fermentation strains through symbiotic fermentation step and solid-liquid separation step, the Hyaluronidase inhibitor of gained can be applied to composition for external application, or for preparing the Orally administered composition or medical composition of suppression hyaluronidase.
Description
Technical field
It is more particularly to a kind of from the saturating of symbiotic fermentation product the present invention relates to a kind of Hyaluronidase inhibitor
The sour enzyme inhibitor of bright matter and its application in Orally administered composition, composition for external application and medical composition.
Background technology
Hyaluronidase (hyaluronidase；HAase invasin) is also known as, is a group hydrolysis hyaluronic acid
(hyaluronic acid；HA) the general name of glycosidase, is primarily present in animal tissue (such as skin, joint, ligament, eyes
Deng), in virus and microorganism.Hyaluronidase acts predominantly on the N- acetamidos glucose and D- glucose aldehyde of hyaluronic acid
β -1,3, β between acid-Isosorbide-5-Nitrae glycosidic bond, its depolymerization are merged the HA or oligosaccharides for being hydrolyzed into low relative molecular mass (Mr).It is transparent
Matter acid universally present in the various tissues of animal, showing a variety of important physiological functions in body, such as lubricating joint,
Operating, promotion wound healing of regulatory protein matter etc..What is more important, it has good moisture-keeping function, in the same of moisturizing
When, it is good skin penetration enhancer again.Cosmetics containing hyaluronic acid are acknowledged as " bionical cosmetic in the world at present
Product ", " forth generation cosmetics ".
Hyaluronidase, can be general according to optimal reaction pH value, amino acid sequence homology and source, structurally and functionally mechanism
It is divided into three classes, is endo-beta-N-acetyl amido glucuroide, inscribe-beta-glucuronidase enzyme, hyaluronic acid cracking respectively
Enzyme.
Hyaluronidase is the participant of type i allergic reaction and tumor cell proliferation, and it has strong correlation with inflammation, allergy
Property.It can decompose the interstitial of connective tissue, tissue edema, vasopermeability increase, inflammation aggravation.These effect with bacterium and its
The penetrating of product is spread rapidly relevant with inflammation.Therefore, suppress the activity of hyaluronidase, hyaluronic acid can be made not to be decomposed
To maintain its normal physiological function, anti-inflammatory, antiallergy, antineoplastic effect can be reached again.Hyaluronidase also can temporarily drop
The stickiness of low cytoplasm, makes hypodermic injection transfusion, the diffusate of localized accumulated or blood accelerate diffusion and beneficial to absorbing, more may be used
The arthritic symptom of graceful degradation.Therefore, hyaluronidase can also be used as drug diffusion agent and treatment degenerative arthritis
Deng application.Suppress in addition, being added in the preparation (especially, such as aesthetic enhancers and tissue filling agent) containing hyaluronic acid
The additive of hyaluronidase activity, can strengthen the persistence of preparation effect, it is to avoid regularly repeat administration.So, suppression
The exploitation of the additive of hyaluronidase activity processed is significant in pharmacy, health products, cosmetic industry.
Hyaluronic acid, which is decomposed, can cause many diseases, such as allergy, inflammation, degenerative arthritis.It has been currently known
Some Hyaluronidase inhibitors, such as multi-sulfonic mucopolysaccharide, can suppress the enzyme activity of hyaluronidase, make hyalomitome
Acid is not decomposed to maintain its normal physiological function, and anti-inflammatory, antiallergy can be reached again, slows down the work(such as degenerative arthritis
Effect.
It is currently known in natural origin product, Orobanchaceae Cistanche tubulosa, the fruit buckeye of Hippocastanaceae Aesculus, fan
The repeatedly extract such as perfume (or spice), with the activity for suppressing hyaluronidase activity.However, above-mentioned have the natural next of suppression hyaluronidase
Source product is limited for the inhibition of hyaluronidase.
In view of this, a kind of natural origin product of exploitation is needed badly, to provide with the product for suppressing hyaluronidase activity.
The content of the invention
It is an aspect of the present invention to provide a kind of Hyaluronidase inhibitor from symbiotic fermentation product, it is included
Symbiotic fermentation product, and this symbiotic fermentation product is to be walked in vegetalitas culture medium through symbiotic fermentation with a variety of fermentation strains
Rapid and solid-liquid separation step and obtain.
Another aspect of the present invention is to provide a kind of composition for external application, comprising above-mentioned Hyaluronidase inhibitor,
Wherein Hyaluronidase inhibitor is used as active ingredient.
It is used to prepare to have it is a further aspect of the present invention to provide a kind of Hyaluronidase inhibitor and suppresses hyaluronidase
Orally administered composition, it is to be used as active ingredient using above-mentioned Hyaluronidase inhibitor.
It is used to prepare to have it is another aspect of the present invention to provide a kind of Hyaluronidase inhibitor and suppresses hyaluronidase
Medical composition, it is to be used as active ingredient using above-mentioned Hyaluronidase inhibitor.
According to aforementioned aspect of the present invention, a kind of Hyaluronidase inhibitor from symbiotic fermentation product is proposed,
It is obtained in vegetalitas culture medium with a variety of fermentation strains through symbiotic fermentation step and solid-liquid separation step, wherein foregoing common
Raw fermentation step is that in being carried out 70 hours to 100 hours at 37 DEG C, and aforesaid fermentation bacterial strain is selected from by various lactobacillus bacterial strain
And at least one non-lactobacillus strains be grouped at least 8.
According to one embodiment of the invention, above-mentioned lactic acid bacteria strains include a variety of Bifidobacterium (Bifidobacterium
Spp.) bacterial strain and/or lactobacillus (Lactobacillus spp.) bacterial strain.
According to one embodiment of the invention, above-mentioned Bifidobacterium is selected from by bifidobacterium adolescentis (B.adolescentis；
BCRC 14606 or ATCC 15703, BCRC 14607 or ATCC 15704, BCRC 14608 or ATCC 15705, BCRC
14658 or DSM 20087, and/or BCRC 80247 or ATCC 15706), two fork Bifidobacterium (B.bifidum；BCRC
11844 or DSM 20082, BCRC 11845 or ATCC 29521, BCRC 14613 or ATCC 11863, BCRC 14614 or
ATCC 15696, BCRC 14615 or ATCC 29521, BCRC 14630 or ATCC 35914, and/or BCRC 14670 or DSM
20215), bifidobacterium breve (B.breve；BCRC 11846 or ATCC 15700, BCRC 12584 or CSCC 1900, BCRC
14601 or ATCC 15698, and/or BCRC 14612 or NCDO 1456), bifidobacterium longum (B.longum；BCRC 11847
Or ATCC 15707, BCRC 12585 or CSCC 1901, BCRC 14602 or ATCC 15697, BCRC 14634 or ATCC
15708, and/or BCRC 14664 or DSM 20097) and above-mentioned any combination constituted.
According to one embodiment of the invention, above-mentioned lactobacillus strains are selected from by lactobacillus delbruockii subspecies bulgaricus
(L.delbrueckii subsp.bulgaricus；BCRC 10696 or ATCC 15703, BCRC 12297 or NCDO 970,
BCRC 14007 or NCDO 2074, BCRC 14008 or NCDO 2394, BCRC 14010 or NCDO 2487, BCRC 14069
Or CSCC 2505, and/or BCRC 14071), Lactobacillus helveticus (L.helveticus；BCRC 11052 or IAM 12090,
BCRC 12258 or ATCC 10386, BCRC 12259 or ATCC 12046, BCRC 12296 or NCDO 1844, BCRC
12936 or ATCC 15009, BCRC 14021 or IFO 3809, BCRC 14026 or ATCC 521), Lactobacillus rhamnosus
(L.rhamnosus；BCRC 10940 or ATCC 7469, BCRC 11673 or ATCC 9595, BCRC 12249 or CSCC
2602nd, BCRC 14027 or ATCC 14957, BCRC 14029 or ATCC 21052, BCRC 14068 or CSCC 2608, BCRC
16000 or ATCC 53103, and/or BCRC 16095 or NCIMB 8824), the secondary cheese subspecies (L.paracasei of lactobacillus
subsp.paracasei；BCRC 12188 or ATCC 27216, BCRC 12193 or ATCC 25598, BCRC 12248 or
ATCC 25302, BCRC 14001 or ATCC 335, BCRC 14023 or ATCC 27092, BCRC 16100 or ATCC
11582nd, BCRC 17002 or ATCC 334, BCRC 17005 or ATCC 11578, and/or BCRC 17475 or IAM
10074), Lactobacillus brevis (L.brevis；BCRC10361 or ATCC 8287, BCRC 11196 or NRRL 1834, BCRC
12187 or ATCC 14869, BCRC 12310 or ATCC 367, and/or BCRC 14060 or DSM 1268), Lactobacillus casei
(L.casei；BCRC 10358 or IAM 1045, BCRC 10697 or ATCC 393, BCRC 11197 or NRRL 1445, BCRC
12272 or CSCC 2607, and/or BCRC 14025 or ATCC 27139), lactobacillus (Lactobacillus sp.；BCRC
12945th, BCRC 14018 or IFO 14511, BCRC 14031 or ATCC 33222, BCRC 14040 or ATCC 27305,
BCRC 14044 or IFO 3914, BCRC 14045 or ATCC 27306, BCRC 14061 or ATCC 8291, and/or
BCRC17003 or ATCC 14435) and above-mentioned any combination constituted.
According to one embodiment of the invention, above-mentioned at least one non-lactobacillus strains include streptococcus (Streptococcus
Spp.) bacterial strain and/or Blastocystis (Saccharomyces spp.) bacterial strain.
According to one embodiment of the invention, above-mentioned Streptococcus strain includes streptococcus thermophilus (Streptococcus
salivarius subsp.thermophilus；BCRC 12257 or CSCC 2012, BCRC 12268 or CSCC 2002,
BCRC 12307 or NCDO 1409, BCRC 13869 or ATCC 19258, BCRC 14017 or ATCC 14485, BCRC
14308 and/or BCRC 14085).
According to one embodiment of the invention, above-mentioned Blastocystis bacterial strain includes saccharomyces cerevisiae (Saccharomyces
cerevisiae；BCRC 20262, BCRC 20263, BCRC 20270 or ATCC 2345, BCRC 20271 or ATCC
26602nd, BCRC 20405 or ATCC 26603, BCRC 20496 or ATCC 28683, BCRC 20497 or ATCC 28684,
BCRC 20498 or ATCC 28685, and/or BCRC 21680 or CBS 5816).
According to one embodiment of the invention, above-mentioned fermentation strain may be, for example, 3 weight hundred in the inoculum concentration of vegetalitas culture medium
Divide ratio to 5 percentage by weights.
According to one embodiment of the invention, above-mentioned vegetalitas culture medium comprising soybean, sesame, Job's tears, sucrose, sodium chloride and
Water.
According to one embodiment of the invention, soybean of the above-mentioned vegetalitas culture medium comprising 1.0 to 10.0 percentage by weights, 1.0
Sesame, the Job's tears of 1.0 to 5.0 percentage by weights, the sucrose of 1.0 to 5.0 percentage by weights to 5.0 percentage by weights and
The sodium chloride of 0.1 to 2.0 percentage by weight.
According to one embodiment of the invention, soybean of the above-mentioned vegetalitas culture medium comprising 1.0 to 6.0 percentage by weights, 1.0 to
The sesame of 3.0 percentage by weights, the Job's tears of 1.0 to 3.0 percentage by weights, the sucrose and 0.2 to 1.0 of 2 to 5 percentage by weights
The sodium chloride of percentage by weight.
According to another aspect of the invention, it is proposed that a kind of Hyaluronidase inhibitor, which is used to prepare to have, suppresses hyaluronic acid
The Orally administered composition of enzyme, it is to be used as active ingredient using above-mentioned Hyaluronidase inhibitor.
According to another aspect of the invention, a kind of composition for external application is proposed, it presses down comprising above-mentioned hyaluronidase
Preparation, it is to be used as active ingredient using above-mentioned Hyaluronidase inhibitor.
In accordance with a further aspect of the present invention, propose that a kind of Hyaluronidase inhibitor is used to prepare to have and suppress hyaluronic acid
The medical composition of enzyme, it is to be used as active ingredient using above-mentioned Hyaluronidase inhibitor.
Using the Hyaluronidase inhibitor of the present invention, it, which is included, derives from symbiotic fermentation product, and this is from altogether
Hair tonic ferment product is through symbiotic fermentation step and solid-liquid separation step in vegetalitas culture medium using a variety of fermentation strains
, the Hyaluronidase inhibitor of gained has the activity for suppressing hyaluronidase, can be applied to composition for external application, preparation
With the Orally administered composition or medical composition for suppressing hyaluronidase.
Brief description of the drawings
To enable above and other purpose, feature, advantage and embodiment of the invention to become apparent, there is provided accompanying drawing, institute
The detailed description for stating accompanying drawing is as follows：
Fig. 1 illustrates the symbiotic fermentation product of according to embodiments of the present invention 1 experimental example, comparative example 1 and the gained of comparative example 2
HPLC collection of illustrative plates.
Fig. 2A to Fig. 2 C shows experimental example (Fig. 2A), the comparative example 1 according to the embodiment 1 of concentration 1.0~10% of the present invention
After the symbiotic fermentation product of (Fig. 2 B) and comparative example 2 (Fig. 2 C) is co-cultured with 3T3 fibroblasts, hyaluronidase it is transparent
Matter acid zymogram colloid photo.
Embodiment
Described in brought forward, the present invention provides a kind of Hyaluronidase inhibitor from symbiotic fermentation product, and it is included
From symbiotic fermentation product, and this symbiotic fermentation product is through symbiosis in vegetalitas culture medium using a variety of fermentation strains
Fermentation step and solid-liquid separation step and obtain.
Expansion says that the present invention " symbiotic fermentation product " referred to herein refers to various different strains, culture in vitro
Carry out symbiotic fermentation in fermentation substrate, then the product obtained by handling through separation of solid and liquid etc., wherein comprising thalline residual component,
Metabolite etc..
In one embodiment, foregoing symbiotic fermentation product can be connect for example in vegetalitas culture medium with a variety of fermentation strains
After kind, obtained through symbiotic fermentation step and solid-liquid separation step.Described herein to be, not symbiotic fermentation product is certain just
With hyaluronidase activity is suppressed, it need to be verified by experiments and just can confirm that.
In one embodiment, above-mentioned vegetalitas culture medium can comprising such as soybean, sesame, Job's tears, sucrose, sodium chloride and
Water.In one illustrates, above-mentioned vegetalitas culture medium can the soybean comprising 1.0 to 10.0 percentage by weights, 1.0 to 5.0 weight hundred
Divide sesame, the Job's tears of 1.0 to 5.0 percentage by weights, the sucrose of 1.0 to 5.0 percentage by weights and 0.1 to 2.0 weight of ratio
The sodium chloride of percentage, its surplus is water.In another illustration, above-mentioned vegetalitas culture medium can include 1.0 to 6.0 weight percents
The soybean of ratio, the sesame of 1.0 to 3.0 percentage by weights, the Job's tears of 1.0 to 3.0 percentage by weights, the sugarcane of 2 to 5 percentage by weights
The sodium chloride of sugar and 0.2 to 1.0 percentage by weight, its surplus is water.
It is described herein to be, if the usage amount of each composition of vegetalitas culture medium is outside the above range, then without reality
Checking is real, it is impossible to be expected to obtain the symbiotic fermentation product with hyaluronidase activity is suppressed.
In one embodiment, above-mentioned fermentation strain is selected from by the non-lactobacillus bacterium of various lactobacillus bacterial strain and at least one
At least 8 in the group that strain is constituted.In one illustrates, above-mentioned fermentation strain may be, for example, in the inoculum concentration of vegetalitas culture medium
3 percentage by weights to 5 percentage by weights.
According to one embodiment of the invention, above-mentioned lactic acid bacteria strains may include but be not limited to a variety of Bifidobacteriums
(Bifidobacterium spp.) bacterial strain and/or lactobacillus (Lactobacillus spp.) bacterial strain.
In the above-described embodiments, Bifidobacterium can be for example, selected from by bifidobacterium adolescentis (B.adolescentis；
BCRC 14606 or ATCC 15703, BCRC 14607 or ATCC 15704, BCRC 14608 or ATCC 15705, BCRC
14658 or DSM 20087, and/or BCRC 80247 or ATCC 15706), two fork Bifidobacterium (B.bifidum；BCRC
11844 or DSM 20082, BCRC 11845 or ATCC 29521, BCRC 14613 or ATCC 11863, BCRC 14614 or
ATCC 15696, BCRC 14615 or ATCC 29521, BCRC 14630 or ATCC 35914, and/or BCRC 14670 or DSM
20215), bifidobacterium breve (B.breve；BCRC 11846 or ATCC 15700, BCRC 12584 or CSCC 1900, BCRC
14601 or ATCC 15698, and/or BCRC 14612 or NCDO 1456), bifidobacterium longum (B.longum；BCRC 11847
Or ATCC 15707, BCRC 12585 or CSCC 1901, BCRC 14602 or ATCC 15697, BCRC 14634 or ATCC
15708, and/or BCRC 14664 or DSM 20097) and above-mentioned any combination constituted.
In the above-described embodiments, lactobacillus strains can be for example, selected from by lactobacillus delbruockii subspecies bulgaricus
(L.delbrueckii subsp.bulgaricus；BCRC 10696 or ATCC 15703, BCRC 12297 or NCDO 970,
BCRC 14007 or NCDO 2074, BCRC 14008 or NCDO 2394, BCRC 14010 or NCDO 2487, BCRC 14069
Or CSCC 2505, and/or BCRC 14071), Lactobacillus helveticus (L.helveticus；BCRC 11052 or IAM 12090,
BCRC 12258 or ATCC 10386, BCRC 12259 or ATCC 12046, BCRC 12296 or NCDO 1844, BCRC
12936 or ATCC 15009, BCRC 14021 or IFO 3809, BCRC 14026 or ATCC 521), Lactobacillus rhamnosus
(L.rhamnosus；BCRC 10940 or ATCC 7469, BCRC 11673 or ATCC 9595, BCRC 12249 or CSCC
2602nd, BCRC 14027 or ATCC 14957, BCRC 14029 or ATCC 21052, BCRC 14068 or CSCC 2608, BCRC
16000 or ATCC 53103, and/or BCRC 16095 or NCIMB 8824), the secondary cheese subspecies (L.paracasei of lactobacillus
subsp.paracasei；BCRC 12188 or ATCC 27216, BCRC 12193 or ATCC 25598, BCRC 12248 or
ATCC 25302, BCRC 14001 or ATCC 335, BCRC 14023 or ATCC 27092, BCRC 16100 or ATCC
11582nd, BCRC 17002 or ATCC 334, BCRC 17005 or ATCC 11578, and/or BCRC 17475 or IAM
10074), Lactobacillus brevis (L.brevis；BCRC10361 or ATCC 8287, BCRC 11196 or NRRL 1834, BCRC
12187 or ATCC 14869, BCRC 12310 or ATCC 367, and/or BCRC 14060 or DSM 1268), Lactobacillus casei
(L.casei；BCRC 10358 or IAM 1045, BCRC 10697 or ATCC 393, BCRC 11197 or NRRL 1445,
BCRC12272 or CSCC 2607, and/or BCRC 14025 or ATCC 27139), lactobacillus (Lactobacillus sp.；
BCRC 12945, BCRC 14018 or IFO 14511, BCRC 14031 or ATCC 33222, BCRC 14040 or ATCC
27305th, BCRC 14044 or IFO 3914, BCRC 14045 or ATCC 27306, BCRC 14061 or ATCC 8291, and/or
BCRC17003 or ATCC 14435) and above-mentioned any combination constituted.
In the above-described embodiments, at least one non-lactobacillus strains may include such as streptococcus (Streptococcus
Spp.) bacterial strain and/or Blastocystis (Saccharomyces spp.) bacterial strain.
In the above-described embodiments, Streptococcus strain includes streptococcus thermophilus (Streptococcus salivarius
subsp.thermophilus；BCRC 12257 or CSCC 2012, BCRC 12268 or CSCC 2002, BCRC 12307 or
NCDO 1409, BCRC 13869 or ATCC 19258, BCRC 14017 or ATCC 14485, BCRC 14308 and/or BCRC
14085)。
In the above-described embodiments, Blastocystis bacterial strain includes saccharomyces cerevisiae (Saccharomyces cerevisiae；
BCRC 20262, BCRC 20263, BCRC 20270 or ATCC 2345, BCRC 20271 or ATCC 26602, BCRC 20405
Or ATCC 26603, BCRC 20496 or ATCC 28683, BCRC 20497 or ATCC 28684, BCRC 20498 or ATCC
28685, and/or BCRC 21680 or CBS 5816).
Above-mentioned ATCC represents American type culture collection (American Type Culture Collection；
ATCC), BCRC represents Hsinchu, Taiwan Province, China Foodstuff Industrial and Development Inst. living resources and preserved and research center
(Bioresource Collection and Research Center；BCRC), CBS represents dutch royal art and the academy of sciences
Fungal organism center of diversity (Centraalbureau voor Schimmelcultures；CBS), DSM represents German micro- life
Thing and cell culture collection (Deutsche Sammlung von Mikroorganismen und Zellkulturen
GmbH；DSMZ), NRRL represents american agriculture research DSMZ (Agricultural Research Service
Culture Collection；NRRL).CSCC, IAM, IFO, NCDO, NCIMB Ze Weifei worlds deposit mechanism
(international depositary authority；IDA), wherein CSCC represents the federal science of Australia Food Science and work
Industry research tissue (Commonwealth Scientific and Industrial Research Organisation；
CSIR O) portion introduction culture presevation (Starter Culture Collection) center, IAM represent Tokyo Univ Japan should
With institute of microbiology (Institute of Applied Microbiology；IAM) DSMZ, IFO represents Japan
Great Ban Fermentation ferment research institute (Institute for Fermentation；IFO) Organism Depositary, NCDO represents the Dutch world
Cooperation and the sustainable development country committee (National Committee for International Cooperation
and Sustainable Development；NCDO), NCIMB represents Britain's Soviet Union's state-run industrial food of Derain and marine microorganism
Collection (National Collection of Industrial and Marine Bacteria；NCIMB), NRRL generations
The state-run agricultural use research center of table United States Department of Agriculture (National Center for Agricultural Utilization
Research) northern area Journal of Sex Research laboratory (Northern Regional Research Laboratory；Now it is renamed as
Agricultural Research Service collection, Agricultural Research Service (ARS) Culture Collection).
In one embodiment, foregoing symbiotic fermentation step can for example at 37 DEG C carry out 70 hours to 100 hours, so with
It is preferable that 72 hours to 96 hours are carried out at 37 DEG C, to obtain tunning.In another illustration, solid-liquid separation step can be such as
Filtration step or centrifugation step, remove the solid content of tunning, to obtain symbiotic fermentation product.
In other embodiments, it is more alternative to carry out eventually between above-mentioned symbiotic fermentation step and solid-liquid separation step
Only fermentation step.In one illustrates, foregoing termination fermentation step can be carried out 15 minutes for example at 90 DEG C.
In one embodiment, the symbiotic fermentation product alternative of above-mentioned gained carries out known post-processing step, example
Such as concentration step, decolorization process and/or microorganism detection step, hold depending on actual demand.
After the symbiotic fermentation product of above-mentioned gained is assessed through activity test in vitro, it was demonstrated that with suppression hyaluronic acid enzyme activity
Property, therefore the composition of various formulations can be further applied.Suitable composition may include but be not limited to Orally administered composition, skin
Topical composition and/or medical composition.In one embodiment, Orally administered composition, the skin of above-mentioned symbiotic fermentation product
Topical composition and/or medical composition are that, using symbiotic fermentation product as active ingredient, making the composition of above-mentioned formulation has
Suppress the activity of hyaluronidase.It is described herein to be, it is however generally that, being currently known in natural origin product has suppression transparent
Matter phytase activity person, the degree of its inhibitory activity has dosage and time interdependent (dose-and time-dependent) related
Property.However, the symbiotic fermentation product of above-mentioned gained of the invention is when as Hyaluronidase inhibitor, with good water-soluble
Property, without the interdependent related cytotoxicity of dosage, more hyaluronic acid can be completely inhibited under without dosage and time interdependent performance
Enzyme enzymatic activity, thus can provide biological safety it is high, stably, raw body absorbability is good and effective Hyaluronidase inhibitor.
Following with several embodiments to illustrate the application of the present invention, so it is not limited to the present invention, skill of the present invention
Those of ordinary skill in art field, without departing from the spirit and scope of the present invention, can various modifications may be made with change.
Embodiment 1：Prepare symbiotic fermentation product
1. prepare vegetalitas culture medium
First, according to the preparation of table 1 embodiment, the vegetalitas culture medium of comparative example 1 to 2.
Table 1
Before being fermented, the vegetalitas culture medium listed by table 1 can be gone out first with known sterilization by saturated steam under pressure
Bacterium, its process conditions sterilized can be carried out 40 minutes for example at 121 DEG C.Then, at least eight kinds of different fermentation strains are distinguished
Inoculation as in the vegetalitas culture medium of table 1, wherein fermentation strain in total inoculum concentration of vegetalitas culture medium can be 3% (w/v)
To 5% (w/v).
In this embodiment, aforesaid fermentation bacterial strain includes bifidobacterium adolescentis (B.adolescentis；BCRC 14606 or
ATCC 15703, and/or BCRC 14658 or DSM 20087), two fork Bifidobacterium (B.bifidum；BCRC 11845 or
ATCC 29521, and/or BCRC 14615 or ATCC 29521), bifidobacterium breve (B.breve；BCRC 11846 or ATCC
15700, and/or BCRC 14612 or NCDO 1456), bifidobacterium longum (B.longum；BCRC 12585 or CSCC 1901,
And/or BCRC 14602 or ATCC 15697), lactobacillus delbruockii subspecies bulgaricus (L.delbrueckii
subsp.bulgaricus；BCRC 10696 or ATCC 15703, and/or BCRC 14008 or NCDO 2394), the newborn bar of Switzerland
Bacterium (L.helveticus；BCRC 12936 or ATCC 15009, and/or BCRC 14026 or ATCC 521), the newborn bar of rhamnose
Bacterium (L.rhamnosus；BCRC 14068 or CSCC 2608, and/or BCRC 16000), the secondary cheese subspecies of lactobacillus
(L.paracasei subsp.paracasei；BCRC 14023 or ATCC 27092, and/or BCRC 17475 or IAM
10074), Lactobacillus brevis (L.brevis；BCRC 11196 or NRRL 1834, and/or BCRC 12187 or ATCC 14869),
Lactobacillus casei (L.casei；BCRC 10697 or ATCC 393, and/or BCRC 11197 or NRRL 1445), lactobacillus
(Lactobacillus sp.；BCRC 14061 or ATCC 8291, and/or BCRC17003 or ATCC 14435), thermophilus
Bacterium (Streptococcus salivarius subsp.thermophilus；BCRC 12257 or CSCC 2012, and/or
BCRC 13869 or ATCC 19258) and saccharomyces cerevisiae (Saccharomyces cerevisiae；BCRC 20262 and/
Or BCRC 21680 or CBS 5816).The bacterial strain of above-mentioned of the same race but different deposit numbers, respectively selects a kind of bacterial strain different from other
The bacterial strain planted is used in mixed way.
Next, the vegetalitas culture medium after above-mentioned inoculation carries out symbiotic fermentation step, it is small in carrying out 72 at 37 DEG C
Up to 96 hours.Obtained by the symbiotic fermentation product of gained is obtained after fermentation step and solid-liquid separation step is terminated, that is,
Symbiotic fermentation product simultaneously carries out further evaluation.
Embodiment 2：Symbiotic fermentation product is assessed using high performance liquid chroma- tography
1. the analysis product extraction of symbiotic fermentation product
Symbiotic fermentation product obtained by experimental example, comparative example 1 and the comparative example 2 of embodiment 1 is first respectively with 50% acetic acid
Ethyl ester is extracted, then with the filtrate after multilayer (such as 6 layers) filtered through gauze, in being dried 6 hours at 45 DEG C, to obtain symbiotic fermentation life
Into the extraction product of thing test sample, 1mg samples are taken, with 2mL DMSO back dissolvings, to carry out high performance liquid chroma- tography (HPLC) analysis.
2. symbiotic fermentation product test sample extracts the analysis method of product
HPLC analysis conditions are as follows, and its result is as shown in Figure 1：
(i) tubing string is analyzed：Cosmosil C18；
(ii) UV-VIS detectors：Hitachi L-7420；
(iii) Detection wavelength：243nm；
(iv) mobile phase：Elutriant A：Methanol/acetic acid (100/0.5)；
(v) elutriant B：Methanol/water/acetic acid (80/20/0.5)；
(vi) condition of gradient elution：Methanol concentration in 0 to 15 minute from 80% linear increment to 84%, 15 to 30
86% is incremented to again in minute, was incremented to 88% again in 30 to 40 minutes, was incremented to 94% again in 0 to 50 minute, 50
100% is incremented to again in 70 minutes；
(vii) flow velocity：0.7mL/min.
Refering to Fig. 1, the symbiotic fermentation product of the experimental example of its illustrated embodiments 1, comparative example 1 and the gained of comparative example 2
HPLC collection of illustrative plates.From Fig. 1 result, different vegetalitas culture mediums are after the step process such as symbiotic fermentation, its peak Distribution
(peak pattern) is also different.The peak Distribution (peak pattern) that the symbiotic fermentation product of experimental group 1 occurs
Can be as reference, and it is used as the following QC standard for producing symbiotic fermentation product.
Embodiment 3：Assess the activity that symbiotic fermentation product suppresses hyaluronidase (i.e. antiallergic activity is analyzed)
1. cell culture
First, by mouse 3T3 fibroblasts (mouse 3T3fibroblasts；BCRC 60071) it is incubated at containing 10%
Hyclone (fetal calf serum, Hyclone) and 2.5% calf serum (bovine calf serum, Hyclone)
Dulbecco ' s Modified Eagle ' s Medium (DMEM) culture mediums and add 3.7% (w/v) sodium acid carbonate,
0.03% (w/v) glutamic acid (L-glutamine), every milliliter containing 100 units penicillin (penicillin) and 100 milligrams
The antibiotic such as streptomysin (streptomycin), in 37 DEG C, 10%CO2Incubator culture, typically with 1 × 106Individual cell it is thin
Born of the same parents' density is inoculated in 75cm2Culture dish, every three to four days carry out squamous subcultures simultaneously change with fresh culture.Afterwards, about is taken
The 3T3 cells in ten generations, carry out the cell experiment of the symbiotic fermentation product of various concentrations.
2. hyaluronidase activity inhibition analysis method (hyaluronic acid enzyme spectrum analysis；hyaluronan-based
zymography)
By 3T3 mouse fibroblast (mouse 3T3fibroblasts；BCRC 60071) with the experiment of embodiment 1
Example, comparative example 1 to 2 symbiotic fermentation product co-culture, or not with foregoing symbiotic fermentation product (control group) co-culture.Training
Support after 1 or 2 day (24 or 48 hours), take the cell culture fluid of each group, prepare containing sodium hyaluronate electrophoresis film (including
Stacking gel and separating gel), then protein electrophoresis is carried out, the condition of wherein protein electrophorese should be this
In technical field that the present invention belongs to known to those of ordinary skill, do not repeat separately herein.After electrophoresis terminates, by the glue in electrophoresis tank
Piece takes out, and is soaked in cleaning cushioning liquid (washing buffer), in after room temperature concussion cleaning 1 hour, removes cleaning slow
Solution is rushed, is added in reaction cushioning liquid (reaction buffer), concussion reaction 16 hours in 37 DEG C of water-baths.Reaction
After finishing, film is taken out, concussion dyeing 2 in the blue dye liquors (Alcian blue solution) of 0.5% A Erxin is soaked in
After hour, then it is soaked in and takes off in dye cushioning liquid (destaining buffer), takes off dye about 1 to 2 hour high-visible to band
Untill.Afterwards, then with glassine paper mounting it is fixed on acrylic plate, places natural air drying at room temperature, that is, completes symbiotic fermentation life
The analytical procedure that product influences for hyaluronidase activity, its result such as Fig. 2A to Fig. 2 C are extracted into thing test sample.
Refering to Fig. 2A to 2C, it shows experimental example (Fig. 2A), the ratio according to the embodiment 1 of concentration 1.0~10% of the present invention
After symbiotic fermentation product and 3T3 the fibroblasts co-cultivation of example 1 (Fig. 2 B) and comparative example 2 (Fig. 2 C), hyaluronidase
Hyaluronic acid zymogram colloid photo.In Fig. 2A into 2C, M roads represent protein labeling, C0、C24、C48Road is shown respectively
Undressed 3T3 mouse fibroblast is through 0, the hyaluronidase activity after culture in 24,48 hours.
From Fig. 2A to Fig. 2 C result, the symbiotic fermentation product of the experimental example (Fig. 2A) of the embodiment of the present invention 1 exists
1.0~10% concentration (processing 24 hours) is respectively provided with powerful inhibitory action for sodium hyaluronate enzymatic activity, and without dosage according to
Deposit relation.Described herein to be, Fig. 2A not only shows the symbiotic fermentation product of the experimental example of embodiment 1 in vitro with low dosage
(1.0%) the symbiotic fermentation product of experimental example (Fig. 2A), in hyaluronidase activity can be completely inhibited in 24 hours,
1.0~10% concentration all can substantially suppress to sodium hyaluronate enzymatic activity, and its inhibitory action between 1.0~10% concentration not
With dosage correlation.Compared to the hyaluronidase suppression of other known natural origin products with dosage and temporal correlation
Preparation, the symbiotic fermentation product of experimental example of the present invention is clearly significantly more efficient to the inhibitory action of sodium hyaluronate enzyme.As for than
Concentration (processing 48 hour) of the symbiotic fermentation product within 10% compared with example 1 (Fig. 2 B) is lived for the ferment of hyaluronidase
Property there is no any inhibitory action, without protection sodium hyaluronate effect.The symbiotic fermentation product of comparative example 2 (Fig. 2 C) exists
10.0% concentration (processing 24 hours) and 1.0% concentration (processing 48 hours) for sodium hyaluronate enzymatic activity just with compared with
Effective inhibitory action (or even complete activity suppression), but inhibition is far away from experimental example (Fig. 2A).
Because the symbiotic fermentation product of the experimental example of embodiment 1 can substantially suppress the activity of hyaluronidase, with guarantor
The favourable effects of sodium hyaluronate are protected, that is, with the ability that sodium hyaluronate is destroyed by aging action by hyaluronidase is postponed, can
As active ingredient and applied to composition for external application, such as cosmetic composition.
Secondly, the healthy food security that the symbiotic fermentation product of the experimental example of embodiment 1 is announced according to TaiWan, China
Appraisal procedure, with low dosage (3.5g/kg body weight/days), middle dosage (7g/kg body weight/days) and high dose (11.67g/kg body weight/
My god) dosage, using stomach tube oral administration experimental animal (male, female rat, at least three data repeated), carry out 28 days it is sub- slow
Property toxicity test, the phenomenon that do not cause death and bad clinical symptom.Daily body weight evolution and drinking-water, feed consumption,
Form, behavioral activity power and organ-tissue weight are not produced and dose-dependent significant changes.Blood analysis and biochemical pointer inspection
No significant difference between the symbiotic fermentation product and comparative example or control group of the experimental example of the result display feeding embodiment 1 of survey,
Confirm without obvious subchronic toxicity, meet the standard (figure is not illustrated) of foodsafety, and estimate the experimental example of embodiment 1 and be total to
Hair tonic ferment product do not observe harmful effect amounts of reactants (no-observed-adverse-effect-level；
NOAEL) it is 11.67g/kg/ days.
Since the symbiotic fermentation product of the experimental example of embodiment 1 can substantially suppress the activity of hyaluronidase, meet again
The standard of foodsafety, can have the Oral compositions for suppressing hyaluronidase activity as active ingredient, and applied to preparing
Thing and/or medical composition.
In summary, confirmed by above-mentioned several embodiments, the present invention presses down from the hyaluronidase of symbiotic fermentation product
Preparation, is successfully made using a variety of fermentation strains through symbiotic fermentation step and solid-liquid separation step, and the symbiotic fermentation of gained
Product has the activity for suppressing hyaluronidase really, also can further suppress allergy, inflammation, degenerative arthritis, can answer
For composition for external application, prepare with the Orally administered composition or medical composition for suppressing hyaluronidase.
Need to supplement, though the present invention with specific technique, specific analysis method or particular instrument illustratively, explanation
The present invention's has the symbiotic fermentation product for suppressing hyaluronidase activity and its application, only in the technical field of the invention
Any those of ordinary skill understands that the present invention is not limited thereto, without departing from the spirit and scope of the present invention, of the invention
Other techniques, other analysis methods or other instrument also can be used with the symbiotic fermentation product for suppressing hyaluronidase activity
Device is carried out.
From above-described embodiment, Hyaluronidase inhibitor from symbiotic fermentation product of the invention and its should
With, it the advantage is that and obtained using a variety of fermentation strains through symbiotic fermentation step and solid-liquid separation step, the symbiosis hair of gained
Ferment product has the activity for suppressing hyaluronidase, can be applied to composition for external application, prepares with suppression hyaluronic acid
The Orally administered composition or medical composition of enzyme.
Although the present invention is disclosed above with several embodiments, so it is not limited to the present invention, belonging to the present invention
Any those of ordinary skill in technical field, without departing from the spirit and scope of the present invention, can various modifications may be made with change, because
This protection scope of the present invention is defined depending on appended claims to be defined.
Claims (14)
1. a kind of Hyaluronidase inhibitor from symbiotic fermentation product, it is characterised in that the matrix metalloproteinase
Inhibitor is through a symbiotic fermentation step and a solid-liquid separation step in a vegetalitas culture medium with a variety of fermentation strains
, wherein the symbiotic fermentation step be at 37 DEG C carry out 70 hours to 100 hours, and those fermentation strains be selected from by a variety of
Lactic acid bacteria strains and at least one non-lactobacillus strains be grouped at least 8.
2. the Hyaluronidase inhibitor according to claim 1 from symbiotic fermentation product, it is characterised in that institute
Stating lactic acid bacteria strains includes a variety of Bifidobacteriums (Bifidobacterium spp.) bacterial strain and/or lactobacillus
(Lactobacillus spp.) bacterial strain.
3. the Hyaluronidase inhibitor according to claim 2 from symbiotic fermentation product, it is characterised in that institute
Bifidobacterium is stated to be selected from by bifidobacterium adolescentis (B.adolescentis；BCRC 14606 or ATCC 15703, BCRC
14607 or ATCC 15704, BCRC 14608 or ATCC 15705, BCRC 14658 or DSM 20087, and/or BCRC
80247 or ATCC 15706), two fork Bifidobacterium (B.bifidum；BCRC 11844 or DSM 20082, BCRC 11845 or
ATCC 29521, BCRC 14613 or ATCC 11863, BCRC 14614 or ATCC 15696, BCRC 14615 or ATCC
29521st, BCRC 14630 or ATCC 35914, and/or BCRC 14670 or DSM 20215), bifidobacterium breve (B.breve；
BCRC 11846 or ATCC 15700, BCRC 12584 or CSCC 1900, BCRC 14601 or ATCC 15698, and/or BCRC
14612 or NCDO 1456), bifidobacterium longum (B.longum；BCRC 11847 or ATCC 15707, BCRC 12585 or CSCC
1901st, BCRC 14602 or ATCC 15697, BCRC 14634 or ATCC 15708, and/or BCRC 14664 or DSM
And above-mentioned any combination is constituted 20097).
4. the Hyaluronidase inhibitor according to claim 2 from symbiotic fermentation product, it is characterised in that institute
Lactobacillus strains are stated to be selected from by lactobacillus delbruockii subspecies bulgaricus (L.delbrueckii subsp.bulgaricus；
BCRC 10696 or ATCC 15703, BCRC 12297 or NCDO 970, BCRC 14007 or NCDO 2074, BCRC 14008
Or NCDO 2394, BCRC 14010 or NCDO 2487, BCRC 14069 or CSCC 2505, and/or BCRC 14071), Switzerland
Lactobacillus (L.helveticus；BCRC 11052 or IAM 12090, BCRC 12258 or ATCC 10386, BCRC 12259 or
ATCC 12046, BCRC 12296 or NCDO 1844, BCRC 12936 or ATCC 15009, BCRC 14021 or IFO 3809,
BCRC 14026 or ATCC 521), Lactobacillus rhamnosus (L.rhamnosus；BCRC 10940 or ATCC 7469, BCRC
11673 or ATCC 9595, BCRC 12249 or CSCC 2602, BCRC 14027 or ATCC 14957, BCRC 14029 or
ATCC 21052, BCRC 14068 or CSCC 2608, BCRC 16000 or ATCC 53103, and/or BCRC 16095 or
NCIMB 8824), secondary cheese subspecies (the L.paracasei subsp.paracasei of lactobacillus；BCRC 12188 or ATCC
27216th, BCRC 12193 or ATCC 25598, BCRC 12248 or ATCC 25302, BCRC 14001 or ATCC 335, BCRC
14023 or ATCC 27092, BCRC 16100 or ATCC 11582, BCRC 17002 or ATCC 334, BCRC 17005 or
ATCC 11578, and/or BCRC 17475 or IAM 10074), Lactobacillus brevis (L.brevis；BCRC10361 or ATCC
8287th, BCRC 11196 or NRRL 1834, BCRC 12187 or ATCC 14869, BCRC 12310 or ATCC 367, and/or
BCRC 14060 or DSM 1268), Lactobacillus casei (L.casei；BCRC 10358 or IAM 1045, BCRC 10697 or
ATCC 393, BCRC 11197 or NRRL 1445, BCRC 12272 or CSCC 2607, and/or BCRC 14025 or ATCC
27139), lactobacillus (Lactobacillus sp.；BCRC 12945, BCRC 14018 or IFO 14511, BCRC 14031
Or ATCC 33222, BCRC 14040 or ATCC 27305, BCRC 14044 or IFO 3914, BCRC 14045 or ATCC
27306th, BCRC 14061 or ATCC 8291, and/or BCRC17003 or ATCC 14435) and above-mentioned any combination constituted
's.
5. the Hyaluronidase inhibitor according to claim 1 from symbiotic fermentation product, it is characterised in that institute
Stating at least one non-lactobacillus strains includes streptococcus (Streptococcus spp.) bacterial strain and/or Blastocystis
(Saccharomyces spp.) bacterial strain.
6. the Hyaluronidase inhibitor according to claim 1 from symbiotic fermentation product, it is characterised in that institute
Stating Streptococcus strain includes streptococcus thermophilus (Streptococcus salivarius subsp.thermophilus；BCRC
12257 or CSCC 2012, BCRC 12268 or CSCC2002, BCRC 12307 or NCDO 1409, BCRC 13869 or ATCC
19258th, BCRC 14017 or ATCC 14485, BCRC 14308 and/or BCRC 14085).
7. the Hyaluronidase inhibitor according to claim 1 from symbiotic fermentation product, it is characterised in that institute
Stating Blastocystis bacterial strain includes saccharomyces cerevisiae (Saccharomyces cerevisiae；BCRC 20262、BCRC 20263、
BCRC 20270 or ATCC 2345, BCRC 20271 or ATCC 26602, BCRC 20405 or ATCC 26603, BCRC
20496 or ATCC 28683, BCRC 20497 or ATCC 28684, BCRC 20498 or ATCC 28685, and/or BCRC
21680 or CBS 5816).
8. the Hyaluronidase inhibitor according to claim 1 from symbiotic fermentation product, it is characterised in that institute
State fermentation strain in the vegetalitas culture medium inoculum concentration be 3 percentage by weights to 5 percentage by weights.
9. the Hyaluronidase inhibitor according to claim 1 from symbiotic fermentation product, it is characterised in that institute
State vegetalitas culture medium and include soybean, sesame, Job's tears, sucrose, sodium chloride and water.
10. the Hyaluronidase inhibitor according to claim 9 from symbiotic fermentation product, it is characterised in that institute
State the soybean of vegetalitas culture medium comprising 1.0 to 10.0 percentage by weights, the sesame of 1.0 to 5.0 percentage by weights, 1.0
The sucrose of the Job's tears, 1.0 to 5.0 percentage by weights to 5.0 percentage by weights and being somebody's turn to do for 0.1 to 2.0 percentage by weight
Sodium chloride.
11. the Hyaluronidase inhibitor according to claim 9 from symbiotic fermentation product, it is characterised in that institute
State vegetalitas culture medium comprising the soybean of 1.0 to 6.0 percentage by weights, the sesame of 1.0 to 3.0 percentage by weights, 1.0 to
The sodium chloride of the Job's tears of 3.0 percentage by weights, the sucrose of 2 to 5 percentage by weights and 0.2 to 1.0 percentage by weight.
12. a kind of Hyaluronidase inhibitor is used to prepare the Orally administered composition with hyaluronidase activity is suppressed, its feature
Be the Orally administered composition be using the Hyaluronidase inhibitor any one of claim 1 to 11 as one effectively into
Point.
13. a kind of composition for external application, it is characterised in that the composition for external application is included as appointed in claim 1 to 11
Hyaluronidase inhibitor described in one, the wherein Hyaluronidase inhibitor are used as an active ingredient.
14. a kind of Hyaluronidase inhibitor is used to prepare the medical composition with hyaluronidase is suppressed, it is characterised in that
The medical composition is to be used as an active ingredient using the Hyaluronidase inhibitor any one of claim 1 to 11.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610108181.9A CN107137628B (en) | 2016-02-26 | 2016-02-26 | Hyaluronidase inhibitor derived from symbiotic fermentation product and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610108181.9A CN107137628B (en) | 2016-02-26 | 2016-02-26 | Hyaluronidase inhibitor derived from symbiotic fermentation product and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107137628A true CN107137628A (en) | 2017-09-08 |
| CN107137628B CN107137628B (en) | 2021-01-05 |
Family
ID=59783019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610108181.9A Active CN107137628B (en) | 2016-02-26 | 2016-02-26 | Hyaluronidase inhibitor derived from symbiotic fermentation product and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107137628B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109172613A (en) * | 2018-08-14 | 2019-01-11 | 景岳生物科技(中国)有限公司 | The topical compositions of the dead bacterium culture containing lactobacillus, medical composition and its in promoting wound healing and reduce the purposes of scar |
| CN112195210A (en) * | 2020-10-24 | 2021-01-08 | 上海加新生物科技有限公司 | Production method of hyaluronic acid |
| CN113150069A (en) * | 2021-02-24 | 2021-07-23 | 安杰利(重庆)生物科技有限公司 | Hyaluronidase inhibitor and preparation method thereof |
| TWI785854B (en) * | 2021-10-21 | 2022-12-01 | 領航生技股份有限公司 | A lactobacillus strain for producing hyaluronic acid, and an application and a composition thereof |
| CN116574634A (en) * | 2023-03-13 | 2023-08-11 | 广东悦创生物科技有限公司 | Streptococcus salivarius thermophilus subspecies JF2 and application thereof in preparation of anti-inflammatory and lipid-relieving food and drug |
| CN118027167A (en) * | 2024-02-18 | 2024-05-14 | 北京越思生物科技有限公司 | Preparation method of active probiotic freeze-dried powder and application of active probiotic freeze-dried powder in cosmetics and medicines |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005253463A (en) * | 2004-02-09 | 2005-09-22 | Toyo Shinyaku:Kk | Fermented product of acerola |
| CN101304724A (en) * | 2005-10-20 | 2008-11-12 | 生物领先公司 | Hyaluronidase inhibitor containing poly-gamma-glutamic acid as an effective component |
| JP2009013240A (en) * | 2007-07-03 | 2009-01-22 | Chisso Corp | Polysaccharide, method for producing the same and its application |
| JP2012012367A (en) * | 2010-07-05 | 2012-01-19 | Toyo Shinyaku Co Ltd | Hyaluronidase activity inhibitor |
| KR101485896B1 (en) * | 2014-10-27 | 2015-01-26 | 주식회사 더트루메틱 | Cosmetic composition for improving anti-oxidation, anti-inflammatory and atopic skin and method of preparing the same |
-
2016
- 2016-02-26 CN CN201610108181.9A patent/CN107137628B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005253463A (en) * | 2004-02-09 | 2005-09-22 | Toyo Shinyaku:Kk | Fermented product of acerola |
| CN101304724A (en) * | 2005-10-20 | 2008-11-12 | 生物领先公司 | Hyaluronidase inhibitor containing poly-gamma-glutamic acid as an effective component |
| JP2009013240A (en) * | 2007-07-03 | 2009-01-22 | Chisso Corp | Polysaccharide, method for producing the same and its application |
| JP2012012367A (en) * | 2010-07-05 | 2012-01-19 | Toyo Shinyaku Co Ltd | Hyaluronidase activity inhibitor |
| KR101485896B1 (en) * | 2014-10-27 | 2015-01-26 | 주식회사 더트루메틱 | Cosmetic composition for improving anti-oxidation, anti-inflammatory and atopic skin and method of preparing the same |
Non-Patent Citations (1)
| Title |
|---|
| ENJURO HARUNARI等: "Hyaluromycin, a New Hyaluronidase Inhibitor of Polyketide Origin from Marine Streptomyces sp.", 《MAR. DRUGS》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109172613A (en) * | 2018-08-14 | 2019-01-11 | 景岳生物科技(中国)有限公司 | The topical compositions of the dead bacterium culture containing lactobacillus, medical composition and its in promoting wound healing and reduce the purposes of scar |
| CN109172613B (en) * | 2018-08-14 | 2022-04-22 | 景岳生物科技(中国)有限公司 | Skin external composition containing lactobacillus dead bacteria culture and its use for promoting wound healing and reducing scar generation |
| US11318176B2 (en) | 2018-08-14 | 2022-05-03 | Genmont Biotech Incorporation | Topical composition, pharmaceutical composition containing inactivated culture and method of facilitating wound healing and scar reduction using the same |
| CN112195210A (en) * | 2020-10-24 | 2021-01-08 | 上海加新生物科技有限公司 | Production method of hyaluronic acid |
| CN113150069A (en) * | 2021-02-24 | 2021-07-23 | 安杰利(重庆)生物科技有限公司 | Hyaluronidase inhibitor and preparation method thereof |
| TWI785854B (en) * | 2021-10-21 | 2022-12-01 | 領航生技股份有限公司 | A lactobacillus strain for producing hyaluronic acid, and an application and a composition thereof |
| CN116574634A (en) * | 2023-03-13 | 2023-08-11 | 广东悦创生物科技有限公司 | Streptococcus salivarius thermophilus subspecies JF2 and application thereof in preparation of anti-inflammatory and lipid-relieving food and drug |
| CN116574634B (en) * | 2023-03-13 | 2023-11-03 | 广东悦创生物科技有限公司 | Streptococcus salivarius thermophilus subspecies JF2 and application thereof in preparation of anti-inflammatory and lipid-relieving food and drug |
| CN118027167A (en) * | 2024-02-18 | 2024-05-14 | 北京越思生物科技有限公司 | Preparation method of active probiotic freeze-dried powder and application of active probiotic freeze-dried powder in cosmetics and medicines |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107137628B (en) | 2021-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107137628A (en) | Hyaluronidase inhibitor and its application from symbiotic fermentation product | |
| Xiao et al. | Enhancement of the antioxidant capacity of soy whey by fermentation with Lactobacillus plantarum B1–6 | |
| EP2474237B1 (en) | Equol-containing fermentation product of soybean embryonic axis, and method for production thereof | |
| US9394513B2 (en) | Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant | |
| KR101492003B1 (en) | Probiotics of Lactobacillus plantarum HY7714 for skin wrinkle inhibitory and moisurizing effects and use of thereof as skin anti-wrinkle or moisturizing products | |
| JP5791009B2 (en) | Lactic acid bacteria and food or drink using them | |
| US8088369B2 (en) | Anti-wrinkle agent | |
| JP5270122B2 (en) | Acidic mucopolysaccharide-producing microorganism, method for producing acidic mucopolysaccharide, and whitening agent containing acidic mucopolysaccharide as an active ingredient | |
| CN104894005B (en) | The lactic acid bacteria BL21 and preparation method and application of a kind of high-yield extracellular polysaccharide | |
| TWI689585B (en) | Novel lactic acid strain and immune activating agent containing novel lactic acid strain | |
| CN111534455B (en) | Preparation of lactobacillus sporolysis product and application of lactobacillus sporolysis product in cosmetics | |
| KR101807328B1 (en) | Dna damage repair promoter for oral application, and elastase activity inhibitor for oral application | |
| KR20160092564A (en) | A Cosmetic Composition Having An Antioxidant Activity, Anti-wrinkle, And Moisturizing Effects Contaning A Two-stage Fermentation lysate Product Of Yeast And Lactic Acid Bacteria | |
| CN101560523A (en) | Nutrient compound based on mixed fermented culture of five probiotics | |
| KR20160092569A (en) | A Cosmetic Composition Having An Antioxidant Activity, Anti-wrinkle, And Moisturizing Effects Contaning A Two-stage Fermentation Product Of Yeast And Lactic Acid Bacteria | |
| Vamanu et al. | Antioxidative effects of phenolic compounds of mushroom mycelia in simulated regions of the human colon, in vitro study | |
| CN102740986B (en) | Method for degrading organic material using mother cell lyases formed in association with spore formation of microorganism | |
| TWI701033B (en) | Bundling energy enhancer of collagen fiber | |
| KR20130107940A (en) | Method of producing fermented red ginseng | |
| KR20110135477A (en) | Fermented liquid by saccharomyces sp. having the effects of antioxidation and whitening and method of manufacturing thereof | |
| JPH06211639A (en) | External agent for suppressing melanogenesis | |
| CN104644538B (en) | Radix scutellariae lactobacillus fermentation, the cosmetics containing fermentate and preparation method and purposes | |
| JP2011168520A (en) | Lactic acid bacterium having melanogenesis inhibitory action and use thereof | |
| JP7426100B2 (en) | External preparation for hair growth or hair loss prevention | |
| JP2018002688A (en) | Composition for enhancing thrombospondin-1 gene expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Chen Lewei Inventor after: Yang Peifen Inventor after: Zhang Yanneng Inventor after: Shi Mingji Inventor before: Chen Lewei Inventor before: Yang Peifen Inventor before: Zhang Yanneng |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |